Research programme: antimalarial compounds - WHO/Japanese antimalarial venture

Drug Profile

Research programme: antimalarial compounds - WHO/Japanese antimalarial venture

Latest Information Update: 16 Nov 2007

Price : $50

At a glance

  • Originator Japanese Ministry of Health, Labour and Welfare; World Health Organization
  • Developer Astellas Pharma; Asubio Pharma; Chugai Pharmaceutical; Daiichi Pharmaceutical; Dainippon Sumitomo Pharma; Eisai Co Ltd; Kitasato Institute; Mitsubishi Pharma Corporation; Sankyo; Shionogi; Takeda
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Malaria

Most Recent Events

  • 18 Oct 2005 No development reported - Preclinical for Malaria in Japan (unspecified route)
  • 01 Oct 2005 Sumitomo Pharmaceuticals has merged with Dainippon Pharmaceutical to form Dainippon Sumitomo Pharma
  • 16 Sep 2005 Daiichi Suntory Pharma has been acquired by Daiichi Pharmaceutical
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top